On June 10, at the site of the 12th China Biological Industry Conference – the branded conference with the largest scale and highest layer in the field of biological industry in China, China Bioengineering Association and HSMP released “China Biomedical Industry Barometer” (CBIB) for the first time in the world.
CBIB was released in China Biological Industry Conference, and the first national-level biomedical industry index came into being
In the opening ceremony and high-layer forum of the 12th China Biological Industry Forum, China Bioengineering Association and HSMAP released “China Biomedical Industry Barometer” (CBIB) to the world for the first time. It is the first national-level index on the development of biopharmaceutical industry established and operated under the instruction of National Development and Reform Committee. In the index, four kinds of composing institutes formulate the tendency line for the industrial development; and it can evaluate the development of biopharmaceutical industry comprehensively, dynamically and in an all-around way; the first batch of selected composing factors include the most representative cities, zones, enterprises and investment institutes in the industry.
▲ The site of the 12th China Biological Industry Conference
▲ CBIB began to generate the daily dynamic lines since January 1 of this year, and the value on June 10 was 7440 points, which increased for 0.15% than that in the last month.
CBIB uses the numerical criteria to create the “wind indicator” for the high-quality development of biopharmaceutical industry. Ma Shuheng, the secretary-general of China Bioengineering Association and Jin Xia, the director of HSMAP licensed for the first batch of composing instituters, including Guangzhou Development and Reform Committee, Shanghai Zhangjiang Biomedicine Base, Beijing Yizhuang Biomedicine Park, Chengdu Hi—tech Development Zone, Wuhan Donghu Hi-tech Development Zone, Beijing Zhongguancun Life Science Park and BioBAY of Suzhou.
L1: Ma Shuheng, the secretary-general of China Bioengineering Association R1: Jin Xia, the director of HSMAP
Our era: transformation and incorporation and exploring new scale
The biopharmaceutical industry in China is being transformed and upgraded from the phase of high-speed growth to the phase of high-quality development currently. In order to understand and evaluate the biopharmaceutical industry in the aspect of high-quality development, we should not only evaluate in economic perspective, but also in innovative and cluster prospective; we should not only evaluate in the manufacturing section, but also in the sections in full industrial chain such as R&D and service; we should not only evaluate based on development foundation, but also evaluate based on development potential; we should not only evaluate the time-point status, but also evaluated the tendency and dynamic conditions.
We should break through the unique economic, manufacturing and current status perspective and being suitable for the tendency of accelerated industrial innovation, collection and incorporation and project new features and requirements, therefore we need to construct a numerical criteria and create the “wind indicator” of high-quality development; it should not only lead the macro tendency with dynamic conditions, but also measure and decide the development phase and development gap in micro prospective.
▲ The new demands for the transformation and incorporating development of the biopharmaceutical industry in China
The idea of CBIB: to realize the comprehensive, quantitative and real-time supervision and prognosis
After the construction, rectification and fitting for two years and half and based on four kinds of composing institutes (city, park, enterprise, capital), China Biomedical Industry Barometer (CBIB) perform the comprehensive, quantitative and real-time supervision to the situations of innovation, economy, cluster and capital of the biopharmaceutical industry in the aspects of economy, innovation and elements, and it can support the macro quantitative decision-making and the research on industrial development in a quantitative way.
▲ The constructing procedure of CBIB
▲ The construction idea of CBIB
The framework of CBIB: four kinds of composing institutes and 8 dynamic indexes
CBIB is the development index evaluating the industry comprehensively, dynamically and in an all-around way based on the fixed base number, which is calculated with 50 weighed indexes from four kinds of composing institutes and the dynamic tendency line, which is generated from 8 dynamic indexes. The selection of the composing institutes of CBIB comes from 36 main representative cities, 24 industrial parks, 456 enterprises and 48 specialized investment institutes in the field of biopharmaceutical industry in China, and it sets some evaluating indexes such as economy, innovation and element. According to the presentation of index data on city, park, enterprise and capital in 2018, 20 composing cities, 20 composing parks, 60 composing enterprise and 20 composing capitals have been determined.
▲ CBIB system
The composing cities come from 36 major cities which collect biopharmaceutical industry in China, and they are generated by screening with the evaluation system including 3 level-one indexes and 22 level-two indexes such as economic strength, innovation capability and element resources. The 36 major cities possess 62% of the biopharmaceutical enterprises in China; the turnover of the listed enterprises take up for 77% of the total turnover of the listed biopharmaceutical enterprises in China; the certificate of class-one new medicine takes up for 69% of the total number in China.
▲ The index system of the composing cities
The composing parks are considered based on comprehensiveness, authority and representativeness, and by the on-site investigation and inspection in the parks and the list on biological industry parks released by the biomedical industrial bases and various institutes licensed by relevant state ministries, we have determined 74 major parks, and 20 composing parks have been generated by screening with the index system including 2 level-one indexes and 11 level-two indexes such as enterprise strength and innovation capability.
▲ The index system of composing parks
The composing enterprises are selected based on 456 enterprises and 60 composing enterprises are generated by screening with data evaluation in 11 indexes, including economic strength, innovative strength and financing strength, etc.
▲ The index system of composing enterprise
The composing capital is determined according to the situation of investment institutes of the biopharmaceutical industry and 20 composing capitals are screened from 48 representative investment institutes in terms of the proportion of PC/VC investment sum with the evaluation system including 2 level-one indexes and 6 level-two indexes including investment strength and investment effects. The total amount of investment projects on medical and health industry in China of these 48 investment institutes takes up for 70.1% of the total number in China; and the total sum of investment projects takes up for 44.3% in the total amount in the field of medical and health in China; the amount of successful listed projects takes up for 70.2% in the total amount of China.
▲ The index system of composing capital
The application and explanation of CBIB index
CBIB index has the functions of tendency prognosis, regional benchmarking, enterprise supervision and capital direction definition. It can predict and decide the industrial development tendency for governmental department and form the entire portrait for regional industrial development; it can analyze the industrial situation for the researching institutes, and perform the regional research and risk factor propaganda and invention based on the database; it can position the development coordinates for the industrial zones, make the difference more accurate as well as create the individualized routine for reference; it can decide the general tendency of the industry for the investment institutes, and form the decision and evaluation coordinate system for the enterprise and find out the opportunity for investment.
▲ The application and explanation of the composing indexes of CBIB
The expectation of CBIB indexes
In the future, CBIB will be continually adjusted and optimized according to the actual situation, and this index will be more mature, steady, forward-looking and predictive, and the more accurate data can serve the development of biopharmaceutical industry in a better way. We will work continually to make a deep explanation to the composing cities and composing parks, to extract the generality of the same kind of parks and cities, and to research the index for the global biopharmaceutical industry.
Table 1 The composing cities in CBIB (in alphabetical order)
Table 2 The composing parks in CBIB (in alphabetical order)
Table 3 The composing enterprises in CBIB (in alphabetical order)
Table 4 The composing capitals in CBIB (in alphabetical order)
Scan the QR code to enter the official WeChat
For more information about the China Bioindustry Convention,
please consult the official website of the Convention, www.biochina-gz.com